key: cord-0958195-rehk1di9 authors: Altable, Marcos; de la Serna, Juan Moisés title: Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets date: 2021-02-22 journal: Virus Res DOI: 10.1016/j.virusres.2021.198347 sha: 6cccf4c7ebd682074b7d796cd5f2667247bbbf42 doc_id: 958195 cord_uid: rehk1di9 BACKGROUND: There is a marked discrepancy between SARS-CoV-2 seroprevalence and COVID-19 cases and deaths in Africa. MAIN: SARS-CoV-2 stimulates humoral and cellular immunity systems, as well as mitogen-activated protein kinase (MAPK) and nuclear NF-kB signalling pathways, which regulate inflammatory gene expression and immune cell differentiation. The result is pro-inflammatory cytokines release, hyperinflammatory condition, and cytokine storm, which provoke severe lung alterations that can lead to multi-organ failure in COVID-19. Multiple genetic and immunologic factors may contribute to the severity of COVID-19 in African individuals when compared to the rest of the global population. In this article, the role of malaria, NF-kB and MAPK pathways, caspase-12 expression, high level of LAIR-1-containing antibodies, and differential glycophorins (GYPA/B) expression in COVID-19 are discussed. CONCLUSION: Understanding pathophysiological mechanisms can help identify target points for drugs and vaccines development against COVID-19. To our knowledge, this is the first study that explores this link and proposes a biological and molecular answer to the epidemiologic discrepancy in COVID-19 in Africa. The novel coronavirus disease is caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), which rapidly spread globally [1] . As of 21 August 2020, there have been 22,536,278 confirmed cases of COVID-19, including 789,197 deaths, reported to WHO [2] . The disease has a mortality rate of 3.5% although this widely varies across different countries. African mortality from COVID-19 is 1.7%, almost half of the global mortality (3.3%) and three-fold lower than European mortality (5.7%). Uyoga et al. recently reported the seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. This study was the first national and regional estimation of population exposure to SARS-CoV-2 in an African country. Results showed that three urban counties, namely Mombasa, Nairobi, and Kisumu, had the highest prevalence, with 9.3%, 8.5%, and 6.5% respectively, which sharply contrast with the minimal number of COVID-19 cases and deaths reported during the same period. The crude prevalence was 5.6%, while the population-weighted, test-adjusted seroprevalence was 5.2%. The cause of this discrepancy is currently unknown [3] . Various investigations have discussed the vulnerability of African populations to the expansion and higher incidence of COVID-19 since the continent has experienced endemic diseases, such as tuberculosis, human immunodeficiency virus, and malaria in recent decades, in addition to emerging and re-emerging infectious pathogens, such as May stated, "Africa's knowledge and experience of suppressing infectious diseases have been critical to rapidly scaling up an agile response to COVID-19" [8] . This fact is supported by the number of infected and deceased in Africa, which is much lower than expected. Researchers have tried to explain the psychosocial aspect of confinement, saying that the African population has high levels of awareness about the dangers of these pandemics [9] since they have suffered from epidemics in recent years [4] . This, in turn, improved the containment procedures of African health systems, an aspect that cannot fully explain lower mortality in the country; hence, this work analyses possible molecular determinants. Previous coronaviruses (i.e. SARS-CoV and MERS-CoV) were characterized by fast and robust initial virus replication with late IFN generation, resulting in disproportionate inflammatory host response [10] . SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) and a transmembrane serine protease (TMPRSS) as cell entry receptors, followed by a cytokine-related syndrome and acute respiratory distress syndrome (ARDS), which is induced by the hyperactivation of the nuclear factor kappa B (NF-kB) most likely in nonimmune cells, including lung epithelial cells [11] . Then, SARS-CoV-2 stimulates humoral and cellular immunity systems as well as mitogen-activated protein kinase (MAPK) and nuclear NF-kB signalling pathways, which regulate inflammatory gene expression and immune cell differentiation [12] . The result is pro-inflammatory cytokines J o u r n a l P r e -p r o o f release [13] , hyperinflammatory condition, and cytokine storm that provoke severe lung alterations [14, 15] and may result in multi-organ failure in COVID-19 [16] . The Janus kinase signal transducer and activator of transcription JAK/STAT pathway is the principal signalling mechanism for a wide array of cytokines and growth factors. All cytokines need JAK signalling to exert their functions [17] . JAK activation stimulates cell proliferation, differentiation, migration, and apoptosis [18] . JAK/STAT-mediated NF-kB activation by coronaviruses (i.e. SAS-CoV or MERS) is responsible for mediating the production of pro-inflammatory cytokines and chemokines. Therefore, NF-kB plays a key role in the pathogenesis of coronaviruses [19] [20] [21] . It has been observed that tyrosine kinase activity is increased in COVID-19 [22] , which leads to phospholipase C (PLC) activation that actives protein kinase C (PKC). This induces reactive oxygen species (ROS) increase, ROS-mediated NF-kappa B (NF-kB) activation, and mTOR inhibition, which result in the transcriptional activation of NF-kB target genes. These genes include anti-apoptotic and survival factors, positive cell-cycle regulators, and pro-inflammatory genes, leading to cytokine production, which in turn increases autophagy [23, 24] and facilitates viral replication and cytokine storm. A study of host responsive genes (HRG) for SARS-CoV-2 showed that they are especially enriched in IL-17 signalling, cytokine-cytokine receptor interaction, and NF-kB pathways, among other proceses [25] . Research has indicated that the NF-kB pathway, which is induced by several mediators, plays a role in cytokine storm [26] . IL-6 also has a pivotal role in cytokine storm because it activates the JAK/STAT signalling pathway [27] [28] [29] . Elevated serum levels of IL-6 are commonly reported in patients with severe J o u r n a l P r e -p r o o f COVID-19 and correlate significantly with nonsurvivors [30, 31] . Overall, NK-kB, JAK/STAT, and MAPK pathways are critical in COVID-19 pathogenesis. In the following sections, the role of malaria, NF-kB, and MAPK pathways, expression of caspase-12, higher levels of LAIR-1-containing antibodies, and differential glycophorins (GYPA/B) expression in COVID-19 are discussed. The malaria parasite Plasmodium falciparum kills on the order of a million African children each year [32] , and this is a small fraction of the number of infected individuals in the population [32] [33] [34] . In communities where everyone is repeatedly infected with Plasmodium falciparum, host genetic factors account for around 25% of the risk of severe malaria, which is a life-threatening form of the disease [34] . Sporozoites of malaria parasites ensure the endurance of their host cell by preventing apoptosis and inflammation by interfering with the host cell NF-kB pathway [35, 36] and hence several genes involved in the inflammatory response [36] . The parasite also inhibits STAT3, which activates a wide variety of genes that control cell proliferation and survival and whose absence inhibits the acute phase response associated with infections [37] . Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by IL-6 through STAT3 signalling [38] . IL-6, which is crucial for cytokine storm development, is also downregulated by the parasite [39] . Both exoerythrocytic forms (EEFs) and erythrocytic stages of malaria use the same strategies to ensure parasite expansion [36] . Other main gene upregulated by Plasmodium is TMPRSS, which encodes a serine protease needed for SARS-CoV-2 entry into the host cell [40] . Apart from these pathways, the parasite promotes PD-1 expression in T cells with cellextrinsic immunosuppressive functions. Programmed cell death protein 1 (PD-1) is a protein on the surface of cells expressed on activated T cells, B cells, and monocytes that regulates the immune response promoting self-tolerance, suppressing T cell inflammatory activity and likely regulating these cell types [41] . Overexpression of PD1 on T cells is one of the indicators of T cell exhaustion (e.g. in chronic infection) [42] . PD-1 reduces PKC/NF-kB signalling and IL-2 production and induces the expression of ubiquitin ligase E3 that leads to NF-kB degradation and T cell receptor (TCR) internalization [43] . This down-regulation of the immune response may be an essential mechanism that controls T cell responses and might limit severe inflammation in patients with malaria and potentially other acute infections, such as COVID-19. It is though SARS-CoV-2 increases PD-1 expression [44] . Inflammasomes are large macromolecular complexes involved in inflammatory response regulation. They are key signalling platforms that detect pathogenic microorganisms and sterile stressors and activate the highly pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18 [45, 46] . They trigger inflammation by activating, on the one hand, caspase-1 and other caspases that cleave pro-IL-1β and pro-IL-18 into their mature active forms, and on the other hand, NF-kB pathway [46] that results in pro-inflammatory cytokines release [13] . Caspase-12 is a second member of the caspase-1 subfamily that is catalytically inactive in humans; it acts as an inhibitor of both inflammasome and NF-kB pathways [46] . Expression of human caspase-12 is predominantly confined to African descent ( Figure 1 ) and is associated with dampened pro-inflammatory cytokine J o u r n a l P r e -p r o o f 8 production and sepsis-related mortality [47] . Labbé et al. elegantly showed the role of caspase-12 in suppressing inflammatory response to malaria. Caspase-12 limited the immune control of parasite replication and dampened hyperinflammation. Experiments revealed that caspase-12 deficiency causes hyperactivation of NF-kB and enhances IFNgamma production. As regards mechanism, caspase-12 competes with the NF-kB essential modulator (NEMO) for association with the inhibitor-kB (IkB) kinase (IKK)α/β, effectively preventing the formation of the IKK complex and inhibiting downstream transcriptional activation by NF-kB [46] . Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is a member of the immunoglobulin superfamily [48] that inhibits T cell activation [49] . LAIR-1 is expressed on lymphoid and myeloid cells, monocytes, and immature CD34+ progenitor cells [50] . It is also described in alveolar macrophages [51] . LAIR-1 suppresses neutrophil tissue migration and acts as a negative regulator of neutrophil-driven airway inflammation in lung diseases, such as bronchiolitis in respiratory syncytial virus (RSV) [52] . Qin et al. collected blood neutrophil gauge test data of 2976 patients who have been diagnosed with SARS-CoV-2 at Wuhan Huoshenshan Hospital in Wuhan, China. They found that disease deterioration is related to the increase in the abundance and proportion of neutrophils. The percentage of neutrophils and the absolute value of neutrophils in patients with critical illness and death were always higher than those of non-critically ill patients and surviving patients. This indicates that continued excessive activation of neutrophils plays a crucial role in SARS-CoV-2, leading to severe illness and death [25] . Likewise, COVID-19 patients who have died had a significantly higher neutrophil to lymphocyte ratio (NLR). NLR was thus positively correlated with death [53] . Achieng et al. discovered that low transcript expression of LAIR-1 is associated with enhanced susceptibility to malaria anaemia and severity. Blockade of the LAIR-1 inhibitory signal by Plasmodium was also associated with enhanced NF-kB activation and cytokine production [54] . The p65 subunit of NF-kB, constitutively expressed in the nucleus of immune system cells, is retained in the cytoplasm (i.e. inactive form) upon engagement of LAIR-1. This was already evident eight hours after LAIR-1 occupancy. Moreover, a reduction in IkBα phosphorylation, the active form of the NF-kB inhibitor, was observed after LAIR-1 engagement [55] . LAIR-1 activation decreases the boosting levels of critical components of the canonical T cell signalling pathway, including the three MAP kinases ERK1/2, JNK1/2, and p38. All three activate IL-2 gene and promote cellular proliferation [56, 57] , affecting cell development and inflammatory cascades by intervening with the PI3K-AKT pathway. LAIR-1 also inhibits the production of IFN-1 [58] . Activation and increased levels of NK cells have been shown in COVID-19 [59] . cell lysis by resting and activating NK cells [60] . In primary B cells, LAIR-1 leads to decreased cytokine production [61] . Finally, LAIR-1 suppresses cell growth by inhibiting the PI3K-AKT-mTOR axis. LAIR-eukaryotic translation elongation factors (i.e. eEF1A2 and eEF1B2). The mechanisms involved may include LAIR-1 regulation of protein synthesis at the translational level or its action as a modulator that suppresses the PI3K-AKT-mTOR pathway directly [62] . Pieper et al. [63] reported that up to 10% of people living in malaria endemic regions produce antibodies that contain LAIR-1, suggesting a public antibody response. However, less than 1% of European individuals these antibodies (figure 2). High levels of LAIR-1-containing antibodies dominate the response to infection without conferring enhanced protection against febrile malaria. Although LAIR-1 prevalence observed in African individuals may have been promoted by malaria infection, the data suggests that it is the exposure to the malaria parasite that selects the rare LAIR-1 B cells [63] . Glycophorin A and glycophorin B are red blood cell surface proteins; they are both receptors for the parasite Plasmodium falciparum, which is the principal cause of malaria in sub-Saharan Africa [64] . DUP4 is a complex structural genomic variant that carries extra copies of a glycophorin A-glycophorin B fusion gene [65] and reduces the risk of severe malaria by up to 40%. DUP4 is common in Kenyan populations, with allele frequency reaching 10% [66] . DUP4 variant reaches a frequency of 13% in south-eastern African populations and is restricted to East African populations [65] . This variant that reduces the risk of severe malaria by 40% has recently increased in frequency in parts of Kenya, yet it appears to be absent in West Africa [67] . GYPA/B are involved in viral entry into the host cell and leukocyte migration, according to the GeneCards database [68] . They are receptors of several viruses for host invasion. It has been reported that several viruses bind to glycophorin proteins for penetration into the cell, including influenza virus, hepatitis A virus, rotavirus, parvovirus, Sendai virus, reovirus, and encephalomyocarditis (EMC) virus [68] [69] [70] . According to The Human Protein Atlas, GYPA/B are mainly expressed in bone marrow, erythrocytes, neutrophils, lungs, lymphoid tissues, B-and T-lymphocytes, monocytes, spleen, and kidneys. As such, malaria might protect patients against SARS-CoV-2 infection by damping regular virushost recognition through GYPA/B. Multiple genetic and immunologic factors may be involved in the severity of COVID-19 in African individuals compared with the rest of the global population. These factors include direct actions of Plasmodium falciparum in the pathogenesis, expression of caspase-12, higher levels of LAIR-1-containing antibodies, and differential glycophorins expression. Other hypotheses can be added to this, such as chloroquine and its derivative drugs used for malaria, precarious data collection, ACE2 polymorphisms and other genes, and so on. Knowledge of these pathophysiological mechanisms can help identify target points for drugs and vaccines development against COVID-19. To our knowledge, this is the first study exploring the link between these variables and proposing a biological and molecular answer to the epidemiologic discrepancy in COVID-19 in Africa. J o u r n a l P r e -p r o o f A novel coronavirus outbreak of global health concern Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors Looming threat of COVID-19 infection in Africa: act collectively, and fast The COVID-19 epidemic Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses Opening remarks at the media briefing on COVID-19 Africa in the path of Covid-19 Immunopathology of SARS-CoV-2 infection: Immune cells and mediators, prognostic factors, and immune-therapeutic implications COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib Coronavirus infections and immune responses Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions The JAK/STAT signaling pathway Inhibition of NF-B-Mediated Inflammation in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice Increases Survival Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-κB activation Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy Cellular death, reactive oxygen species (ROS) and diabetic complications review-Article Aberrant NF-κB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications Mechanistic insights into SARS-CoV-2 epidemic via revealing the features of SARS-CoV-2 coding proteins and host responses upon its infection Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 Targeting Interleukin-6 Signaling in Clinic Interleukin-6: Designing specific therapeutics for a complex cytokine Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure The global distribution of clinical episodes of Plasmodium falciparum malaria Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa Heritability of malaria in Africa Activation of a PAK-MEK signalling pathway in malaria parasite-infected erythrocytes Plasmodium Circumsporozoite Protein Promotes the Development of the Liver Stages of the Parasite Essential Role of STAT3 in the Control of the Acute-Phase Response as Revealed by Inducible Gene Activation in the Liver Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin-6 via STAT3 signaling in synovial tissues IL-6 induced by IL-1 inhibits malaria pre-erythrocytic stages but its secretion is downregulated by the parasite SARS-CoV-2 and the next generations: which impact on reproductive tissues? Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Overcoming T cell exhaustion in infection and cancer PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8 + T cells COVID-19 and immunological regulations -from basic and translational aspects to clinical implications Activation and regulation of the inflammasomes Dampens the Immune Response to Malaria Independently of the Inflammasome by Targeting NF-κB Signaling Differential modulation of endotoxin responsiveness by human caspase-12 LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes Immune inhibitory receptors Immunoregulatory complement receptor-1 and leukocyte-associated Ig-like receptor-1 expression on leukocytes in Psoriasis vulgaris Soluble leukocyte-associated ig-like receptor-1 in amniotic fluid is of fetal origin and positively associates with lung compliance LAIR-1 limits neutrophilic airway inflammation Characteristics of peripheral blood differential counts in hospitalized patients with COVID-19 Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-κB nuclear translocation in human myeloid leukemias Multiple p21ras effector pathways regulate nuclear factor of activated T cells Leukocyteassociated immunoglobulin-like receptor 1 inhibits T-cell signaling by decreasing protein phosphorylation in the T-cell signaling pathway CD305) on human blood monocytes as a marker of hepatic cirrhosis progression NK cells: A double edge sword against SARS-CoV-2 The inhibitory collagen receptor LAIR-1 (CD305) Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway Public antibodies to malaria antigens generated by two LAIR1 insertion modalities Erythrocyte glycophorins as receptors for Plasmodium merozoites. Parasites and Vectors The Malaria-Protective Human Glycophorin Structural Variant DUP4 Shows Somatic Mosaicism and Association with Hemoglobin Levels A novel locus of resistance to severe malaria in a region of ancient balancing selection Resistance to malaria through structural variation of red blood cell invasion receptors Early scars are forever: Childhood abuse in patients with adult-onset PTSD is associated with increased prevalence and severity of psychiatric comorbidity Hepatitis A Virus -an overview | ScienceDirect Topics